PBYI
Income statement / Annual
Last year (2023), Puma Biotechnology, Inc.'s total revenue was $235.64 M,
an increase of 3.35% from the previous year.
In 2023, Puma Biotechnology, Inc.'s net income was $21.59 M.
See Puma Biotechnology, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$235.64 M
|
$228.00 M
|
$253.20 M
|
$225.10 M
|
$272.30 M
|
$251.00 M
|
$27.70 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$62.68 M |
$55.10 M |
$63.70 M |
$39.40 M |
$36.80 M |
$34.60 M |
$5.60 M |
$1.15 M |
$776,000.00 |
$0.00 |
| Gross Profit |
$172.96 M |
$172.90 M |
$189.50 M |
$185.70 M |
$235.50 M |
$216.40 M |
$22.10 M |
-$1.15 M |
-$776,000.00 |
$0.00 |
| Gross Profit Ratio |
0.73 |
0.76 |
0.75 |
0.82 |
0.86 |
0.86 |
0.8 |
0 |
0 |
0 |
| Research and Development
Expenses |
$50.38 M
|
$52.20 M
|
$71.90 M
|
$97.70 M
|
$132.90 M
|
$164.90 M
|
$207.80 M
|
$222.80 M
|
$208.50 M
|
$122.90 M
|
| General & Administrative
Expenses |
$88.43 M
|
$89.98 M
|
$116.29 M
|
$118.49 M
|
$140.51 M
|
$146.19 M
|
$106.70 M
|
$53.80 M
|
$31.80 M
|
$19.40 M
|
| Selling & Marketing
Expenses |
$881,000.00
|
$22,000.00
|
$6,000.00
|
-$88,000.00
|
$1.19 M
|
$12,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$89.31 M
|
$90.00 M
|
$116.30 M
|
$118.40 M
|
$141.70 M
|
$146.20 M
|
$106.70 M
|
$53.80 M
|
$31.80 M
|
$19.40 M
|
| Other Expenses |
$625,000.00 |
-$28,000.00 |
$300,000.00 |
$400,000.00 |
$200,000.00 |
-$9.70 M |
-$100,000.00 |
-$400,000.00 |
$25,000.00 |
-$14,000.00 |
| Operating Expenses |
$140.32 M |
$142.20 M |
$188.20 M |
$216.10 M |
$274.60 M |
$311.10 M |
$314.50 M |
$276.60 M |
$240.30 M |
$142.30 M |
| Cost And Expenses |
$203.00 M |
$197.30 M |
$251.90 M |
$255.50 M |
$311.40 M |
$345.70 M |
$320.10 M |
$276.60 M |
$240.30 M |
$142.30 M |
| Interest Income |
$2.61 M |
$800,000.00 |
$100,000.00 |
$500,000.00 |
$2.80 M |
$1.80 M |
$1.20 M |
$1.00 M |
$1.00 M |
$300,000.00 |
| Interest Expense |
$13.33 M |
$11.50 M |
$12.80 M |
$14.10 M |
$15.00 M |
$11.00 M |
$700,000.00 |
$958,000.00 |
$971,000.00 |
$324,000.00 |
| Depreciation &
Amortization |
$11.52 M
|
$8.92 M
|
$10.60 M
|
$7.20 M
|
$4.80 M
|
$7.38 M
|
$2.81 M
|
$1.15 M
|
$776,000.00
|
$627,000.00
|
| EBITDA |
$44.78 M
|
$20.97 M
|
-$5.40 M
|
-$38.54 M
|
-$55.72 M
|
-$95.21 M
|
-$288.42 M
|
-$275.45 M
|
-$239.50 M
|
-$141.65 M
|
| EBITDA Ratio |
0.19 |
0.14 |
0.01 |
-0.13 |
-0.13 |
-0.41 |
-10.52 |
0 |
0 |
0 |
| Operating Income Ratio
|
0.14
|
0.1
|
-0.04
|
-0.14
|
-0.14
|
-0.38
|
-10.56
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$9.97 M
|
-$23.26 M
|
-$30.09 M
|
-$29.39 M
|
$53,000.00
|
-$18.92 M
|
$435,000.00
|
$585,000.00
|
$996,000.00
|
$310,000.00
|
| Income Before Tax |
$22.67 M |
$500,000.00 |
-$28.80 M |
-$59.80 M |
-$75.60 M |
-$113.60 M |
-$292.00 M |
-$276.00 M |
-$239.30 M |
-$142.00 M |
| Income Before Tax Ratio
|
0.1
|
0
|
-0.11
|
-0.27
|
-0.28
|
-0.45
|
-10.54
|
0
|
0
|
0
|
| Income Tax Expense |
$1.08 M |
$500,000.00 |
$300,000.00 |
$200,000.00 |
$7.12 M |
-$7.92 M |
-$2.21 M |
-$2.15 M |
-$1.75 M |
-$941,000.00 |
| Net Income |
$21.59 M |
$912,000.00 |
-$29.10 M |
-$60.00 M |
-$82.72 M |
-$113.60 M |
-$292.00 M |
-$276.00 M |
-$239.30 M |
-$142.00 M |
| Net Income Ratio |
0.09 |
0 |
-0.11 |
-0.27 |
-0.3 |
-0.45 |
-10.54 |
0 |
0 |
0 |
| EPS |
0.46 |
0.0204 |
-0.72 |
-1.52 |
-2.13 |
-2.99 |
-7.86 |
-8.29 |
-7.45 |
-4.73 |
| EPS Diluted |
0.45 |
0.0203 |
-0.72 |
-1.52 |
-2.13 |
-2.99 |
-7.86 |
-8.29 |
-7.45 |
-4.73 |
| Weighted Average Shares
Out |
$47.13 M
|
$44.67 M
|
$40.64 M
|
$39.58 M
|
$38.77 M
|
$37.94 M
|
$37.17 M
|
$33.30 M
|
$32.13 M
|
$30.01 M
|
| Weighted Average Shares
Out Diluted |
$47.55 M
|
$44.93 M
|
$40.64 M
|
$39.58 M
|
$38.77 M
|
$37.94 M
|
$37.17 M
|
$33.30 M
|
$32.13 M
|
$30.01 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
